Metropolis Healthcare Ltd
Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
- Market Cap ₹ 8,775 Cr.
- Current Price ₹ 1,694
- High / Low ₹ 2,318 / 1,315
- Stock P/E 60.5
- Book Value ₹ 257
- Dividend Yield 0.23 %
- ROCE 14.8 %
- ROE 12.0 %
- Face Value ₹ 2.00
Pros
Cons
- Promoter holding has decreased over last quarter: -0.51%
- The company has delivered a poor sales growth of 9.22% over past five years.
- Company has a low return on equity of 13.0% over last 3 years.
- Dividend payout has been low at 14.9% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
388 | 456 | 475 | 545 | 647 | 761 | 856 | 998 | 1,228 | 1,148 | 1,208 | 1,331 | |
285 | 339 | 359 | 405 | 467 | 559 | 619 | 708 | 880 | 855 | 920 | 1,028 | |
Operating Profit | 104 | 117 | 116 | 140 | 181 | 203 | 237 | 290 | 348 | 293 | 288 | 303 |
OPM % | 27% | 26% | 24% | 26% | 28% | 27% | 28% | 29% | 28% | 26% | 24% | 23% |
10 | 7 | 29 | 39 | 6 | 8 | -17 | 12 | 34 | 15 | 9 | 15 | |
Interest | 3 | 2 | 2 | 2 | 4 | 4 | 13 | 12 | 25 | 32 | 28 | 19 |
Depreciation | 16 | 21 | 17 | 17 | 19 | 20 | 39 | 46 | 63 | 89 | 94 | 109 |
Profit before tax | 95 | 101 | 128 | 160 | 164 | 187 | 169 | 244 | 293 | 188 | 175 | 191 |
Tax % | 34% | 33% | 36% | 33% | 32% | 34% | 24% | 25% | 27% | 24% | 26% | 24% |
63 | 68 | 82 | 107 | 112 | 124 | 128 | 183 | 215 | 143 | 128 | 146 | |
EPS in Rs | 57.34 | 61.82 | 80.47 | 106.52 | 109.23 | 23.94 | 25.15 | 35.82 | 41.85 | 27.90 | 24.95 | 27.99 |
Dividend Payout % | 2% | 0% | 100% | 49% | 0% | 55% | 32% | 22% | 19% | 29% | 16% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 9% |
3 Years: | 3% |
TTM: | 10% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 0% |
3 Years: | -11% |
TTM: | 14% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 3% |
1 Year: | -14% |
Return on Equity | |
---|---|
10 Years: | 21% |
5 Years: | 17% |
3 Years: | 13% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 292 | 352 | 269 | 314 | 405 | 408 | 513 | 696 | 876 | 978 | 1,086 | 1,321 |
20 | 14 | 5 | 1 | 1 | 18 | 67 | 112 | 379 | 266 | 197 | 204 | |
69 | 87 | 107 | 188 | 110 | 113 | 160 | 181 | 256 | 240 | 254 | 332 | |
Total Liabilities | 391 | 462 | 391 | 512 | 526 | 550 | 750 | 1,000 | 1,521 | 1,495 | 1,547 | 1,867 |
149 | 153 | 142 | 202 | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | 1,447 | |
CWIP | 1 | 0 | 1 | 1 | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 |
Investments | 132 | 168 | 101 | 142 | 102 | 33 | 14 | 10 | 16 | 15 | 55 | 71 |
109 | 141 | 147 | 167 | 216 | 298 | 437 | 647 | 440 | 340 | 316 | 349 | |
Total Assets | 391 | 462 | 391 | 512 | 526 | 550 | 750 | 1,000 | 1,521 | 1,495 | 1,547 | 1,867 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
77 | 69 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 | 263 | |
-61 | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 | -201 | |
-14 | -9 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 | -87 | |
Net Cash Flow | 2 | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 | -25 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 47 | 57 | 54 | 54 | 57 | 66 | 55 | 45 | 40 | 39 | 38 | 41 |
Inventory Days | 47 | 52 | 46 | 38 | 53 | 55 | 44 | 59 | 68 | 64 | 58 | 65 |
Days Payable | 75 | 92 | 96 | 97 | 88 | 90 | 152 | 160 | 136 | 136 | 150 | 171 |
Cash Conversion Cycle | 19 | 17 | 3 | -5 | 21 | 30 | -54 | -56 | -29 | -33 | -53 | -65 |
Working Capital Days | 22 | 32 | 8 | -27 | 28 | 42 | 11 | 4 | 14 | 14 | 7 | 26 |
ROCE % | 28% | 34% | 46% | 43% | 43% | 40% | 36% | 29% | 17% | 16% | 15% |
Documents
Announcements
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
3 Jun - Promoter Dr. Sushil Shah transferred 2.25% shares to family trust via inter-se transfer on May 29, 2025.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
3 Jun - Promoter Sushil Shah Family Trust acquired 2.25% shares from Dr. Sushil Shah on May 29, 2025.
-
Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On June 03, 2025
2 Jun - Cancellation of analyst/institutional investor meeting scheduled for June 3, 2025.
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
31 May - Acquisition of Scientific Pathology delayed by 15 days, update on completion timeline.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 30 May
Annual reports
Concalls
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Dec 2024Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
May 2020Transcript PPT
-
Mar 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Nov 2019TranscriptNotesPPT
-
Sep 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
Aug 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
May 2019Transcript PPT
Leading Diagnostics company[1] Metropolis Healthcare Ltd is the second largest Diagnostic company in India and the largest player in Western and Southern India.